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Motor, cognitive, and functional declines
contribute to a single progressive factor in
early HD
ABSTRACT
Objective: To identify an improved measure of clinical progression in early Huntington disease
(HD) using data from prospective observational cohort studies and placebo group data from ran-
domized double-blind clinical trials.
Methods: We studied Unified Huntington Disease Rating Scale (UHDRS) and non-UHDRS clinical
measures and brain measures of progressive atrophy in 1,668 individuals with early HD followed
up prospectively for up to 30 to 36 months of longitudinal clinical follow-up.
Results: The results demonstrated that a composite measure of motor, cognitive, and global func-
tional decline best characterized clinical progression and was most strongly associated with brain
measures of progressive corticostriatal atrophy.
Conclusions: Use of a composite motor, cognitive, and global functional clinical outcome measure in
HD provides an improved measure of clinical progression more related to measures of progressive
brain atrophy and provides an opportunity for enhanced clinical trial efficiency relative to currently
used individual motor, cognitive, and functional outcome measures. Neurology® 2017;89:2495–2502
GLOSSARY
CARE-HD 5 Co-Enzyme Q10 and Remacemide: Evaluation in HD; COHORT 5 Cooperative Huntington’s Disease Observa-
tional Research Trial; cUHDRS 5 composite Unified Huntington Disease Rating Scale; HD 5 Huntington disease; ICC 5
intraclass correlation; PBA 5 Problem Behaviors Assessment; PCA 5 principal component analysis; SDMT 5 Symbol Digit
Modality Test; S/N 5 signal-to-noise; SWR 5 Stroop Word Reading Test; TFC 5 Total Functional Capacity; TMS 5 Total
Motor Score; 2CARE 5 Coenzyme Q10 (CoQ) in Huntington Disease; UHDRS 5 Unified Huntington Disease Rating Scale.
Affected individuals with Huntington disease (HD) exhibit a triad of neurocognitive deficits,
neuropsychiatric symptoms, and movement disorder, resulting in progressive decrements in
daily functioning1 that affect patients and their caregivers. Large-scale longitudinal studies of
these domains can help inform the choice of clinical outcome measures for randomized trials
aiming to slow clinical progression. Our study goal was to explore each of the affected individual
clinical domains of HD in longitudinal observational and interventional settings and to deter-
mine which outcome measures best met the key criteria of sensitivity to longitudinal clinical
change, association with measures of disease pathophysiology, and broad clinical domain
coverage.
We hypothesized that a multidomain approach may better fulfill these key criteria relative to
an individual clinical domain outcome approach. We focused on the early stage of manifest dis-
ease (i.e., Total Functional Capacity [TFC] stages I and II) because disability might then be
more plausibly reversed or slowed, and this stage represents the cohort of participants most com-
monly recruited at present for trials aiming to slow clinical progression. We studied in total
1,668 individuals with up to 36 months of longitudinal clinical follow-up using all available
clinical outcome measures from the Unified Huntington Disease Rating Scale (UHDRS)2
and other non-UHDRS clinical measures.
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The results suggested that relative to all clin-
ical measures investigated, a composite made
up of 4 measures spanning the affected
cognitive, motor, and global functional do-
mains from the UHDRS exhibited the best
signal-to-noise (S/N) ratio, the best relationship
to measures of progressive brain atrophy char-
acteristic of HD, and the best domain coverage
in an early HD population. We label this out-
come the composite UHDRS (cUHDRS), and
here, we present the analyses to support its val-
idity and use in clinical trials in early HD.
METHODS These analyses used data from 1,668 individuals
with early-stage manifest HD (TFC score 7–13) and 265 con-
trols with longitudinal clinical ratings follow-up of up to 30 months
(Co-Enzyme Q10 and Remacemide: Evaluation in HD [CARE-
HD]3) or up to 36 months (TRACK-HD,4 Cooperative Hun-
tington’s Disease Observational Research Trial [COHORT],5 and
Coenzyme Q10 (CoQ) in Huntington Disease [2CARE]6) (see
table 1 for demographics and sample size and table e-1 at
Neurology.org for longitudinal loss to follow-up data). The 4
studies had multiple sites in 6 nations: TRACK-HDhad 4 sites in 4
countries (Canada, France, England, and the Netherlands);
COHORT had 44 sites in 3 countries (Australia, Canada, and the
United States); CARE-HD had 23 sites in 2 countries (Canada and
the United States); and 2CARE had 48 sites in 3 countries
(Canada, Australia, and the United States).
Standard protocol approvals, registrations, and patient
consents. All data were originally collected with appropriate pre-
approval of human ethics committees and written informed con-
sent at each site in each respective study.
Statistical methods. The 3-year TRACK-HD observational
study contained the most comprehensive dataset of clinical
measures, including the TFC, Total Motor Score (TMS), Symbol
Digit Modality Test (SDMT), Stroop Word Reading Test
(SWR), 5 quantitative motor indexes, an emotion recognition
test, and the Problem Behaviors Assessment (PBA) and PBA-
apathy scores. Thus, it was used as a training dataset for all
analyses to generate hypotheses, which were then independently
confirmed in the larger COHORT observational study. Appli-
cability to the clinical trial setting was investigated by confirma-
tion in the independent CARE-HD and 2CARE clinical trial
studies. Additional details on study selection criteria, outcome
measures, and the statistical methodology below described are
available in the e-Methods.
Comparing longitudinal changes of individual measures
using the S/N ratio. We used the S/N ratio, defined as the
mean change from baseline to a given time divided by the
Table 1 Baseline clinical characteristics: TRACK-HD, COHORT, CARE-HD, and 2CARE
Study No. Female, % Age, y CAG TFC TMS SDMT SWR cUHDRS
TRACK-HD 123 45 48.8 (9.8) 43.7 (3.0) 10.9 (2.0) 23.7 (10.8) 33.6 (10.2) 78.3 (19.5) 11.7 (2.9)
COHORT 1,067 50 50.2 (12.2) 43.5 (4.8) 10.2 (2.0) 30.7 (15.7) 27.9 (11.5) 65.5 (21.0) 9.8 (3.3)
CARE-HD 173 47 47.5 (10.7) 45.1 (4.6) 10.1 (1.8) 31.5 (14.1) 25.2 (9.2) 62.8 (17.7) 9.3 (2.9)
2CARE 306 54 50.7 (11.6) 43.9 (3.8) 11.0 (1.4) 27.4 (13.9) 30.0 (12.1) 65.1 (18.5) 10.6 (2.9)
Abbreviations: CARE-HD 5 Co-Enzyme Q10 and Remacemide: Evaluation in HD; COHORT 5 Cooperative Huntington’s Disease Observational Research
Trial; cUHDRS 5 Unified Huntington Disease Rating Scale; SDMT 5 Symbol Digit Modality Test; SWR 5 Stroop Word Reading Test; TFC 5 Total Functional
Capacity; TMS 5 Total Motor Score; 2CARE 5 Coenzyme Q10 (CoQ) in Huntington Disease.
Values are mean (SD) when appropriate.
Figure 1 Longitudinal S/N ratio of UHDRS and non-UHDRS clinical measures in
early HD (stages I and II at baseline) across the motor, quantitative
motor, cognitive, behavior, and global functional domains in the
TRACK-HD sample
HD5 Huntington disease; PBA5 Problem Behaviors Assessment; SDMT5 Symbol Digit Modal-
ity Test; S/N 5 single-to-noise; SWR 5 Stroop Word Reading Test; TFC 5 Total Functional
Capacity; TMS 5 Total Motor Score; UHDRS 5 Unified Huntington Disease Rating Scale.
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corresponding SD. Thus, the S/N ratio is a measure of the
strength of the longitudinal change relative to the random vari-
ability of change for a given measure. A larger S/N ratio indicates
greater reliable variance, which is a desirable characteristic for the
general use of a clinical endpoint.7
Building a multidomain outcome variable from individual
components. To understand the relationship among the individ-
ual clinical variables in TRACK-HD that had a pattern of regular
progression with high S/N, we first evaluated their association by
calculating the Pearson correlation coefficient and 2-sided statistical
significance (a set to 0.05) among each pair of variables using
baseline and all available time points. We then performed a prin-
cipal component analysis (PCA) that served as the basis to define
a composite outcome variable as a linear combination of stan-
dardized individual variables. The multidomain composite gener-
ated from our PCA is the cUHDRS. In a supplemental analysis, the
S/N ratio of all possible combinations of the cUHDRS relative to
its individual components was investigated. We further quantified
the differences in S/N between the cUHDRS and each individual
component using a bootstrapping method.
Establishing the clinicometric properties of the cUHDRS.
The cUHDRS was tested against different clinical criteria, includ-
ing sensitivity to disease stage; association with brain imaging
changes relative to individual measures; pattern, consistency,
and magnitude of longitudinal change in early HD across the
datasets; and test-retest reliability with short-term data. We
investigated with meta-analyses using both fixed-effect and
random-effect models the pattern of longitudinal change at each
available time point for the cUHDRS vs its individual component
measures. The utility of the cUHDRS compared to its individual
measures was evaluated in hypothetical 2- vs 3-year trials, and
sample sizes were estimated.
RESULTS Results from analyses of the TRACK-HD
dataset showed that the TMS, TFC, SDMT, and
SWR had relatively high longitudinal S/N ratios
(z0.6–0.9 at the 2-year follow-up) compared to all
other measures (figure 1). Emotion recognition, PBA
composite behavior, circle tracing, and certain
quantitative motor indexes, including grip force var-
iability and tongue force variability, had low S/N
ratios (#0.3 at the 2-year follow-up). Indexes of
tapping and the PBA-apathy score had S/N in an
intermediate range (z0.5 at the 2-year follow-up).
Similar analyses were performed in the healthy
control group and showed that all measures had no
significant progression over time (figure e-1).
The correlational analyses from TRACK-HD
baseline data of the top-performing clinical measures
revealed that the TMS, SDMT, and SWR scores were
all significantly and strongly associated with each
other and with the TFC score (all Pearson r 5
0.41–0.59, all p , 0.001; table e-2). The PBA-
apathy score was significantly although more weakly
associated with the TFC, TMS, SDMT, and SWR
scores (r 5 0.22–0.41; table e-2). The relative
strength of the associations was the same between
the clinical variables when all available time points
were used: the correlation coefficients ranged from
0.53 to 0.65 among the SDMT, SWR, TMS, and
TFC, whereas the association between PBA-apathy
and other variables was between 0.25 and 0.35.
A PCA performed on TMS, TFC, SDMT,
SWR, and PBA-apathy showed that TMS, TFC,
SDMT, and SWR had loadings of similar size for
the primary principal component, which ac-
counted for most of the observed variability
(z60%) (figure e-2). Principal component 2 ex-
plained onlyz18% of the variability and was asso-
ciated mainly with apathy. The PCA results were
consistent whether derived with data from all time
points together or only baseline data (figure e-2).
The overall pattern of the correlations and the PCA
results indicated that TMS, TFC, SDMT, and
SWR had significant overlap, but PBA-apathy did
not. This provided the rationale for generating the
modified UHDRS composite score among the do-
mains of functioning, cognition, and motor with
the following formula:
cUHDRS5

TFC2 10:4
1:9

2

TMS2 29:7
14:9

1

SDMT2 28:4
11:3

1

SWR2 66:1
20:1

1 10
Note the negative sign for (scaled) TMS and the
positive sign for all other variables. The centering
and scaling constants for each individual variable were
derived from pooled baseline data of TRACK-HD,
COHORT, CARE-HD, and 2CARE. An offset of
10 was used to allow the composite measure to take
on positive values in the longitudinal follow-up peri-
ods of all the studies.
The observed difference in the S/N ratio
between the cUHDRS and each individual compo-
nent in TRACK-HD was numerically superior in
all cases (e.g., 26%–38% larger than the best indi-
vidual measure, which was the TMS at 24 and 36
months, respectively) and in 10 of 12 comparisons,
the S/N ratio difference between the cUHDRS and
its individual components was statistically signifi-
cant (p , 0.05; figure 2A and table e-3).
Confirming TRACK-HD findings in 3 independent
studies (COHORT, CARE-HD, and 2-CARE). The data
analyses described for the TRACK-HD study were
applied to the COHORT, CARE-HD, and 2CARE
datasets (figure 2, B–D). The results showed an
increase in the S/N ratio of the cUHDRS compared to
its individual components for all comparisons and
a statistically significant increase in 26 of 36 (p, 0.05)
total comparisons across the datasets, with 15 of these
comparisons highly significant (p , 0.001). Four of
the remaining 10 comparisons had 0.05 , p , 0.10
(table e-3). Because each of the additional studies
contained complete Stroop assessments (TRACK-HD
lacked the color naming and interference
Neurology 89 December 12, 2017 2497
ª 2017 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
components), a supplemental analysis compared the S/
N ratio for the different components and showed that
in most cases the S/N ratios for color naming and
interference variables were low relative to that of the
SWR variable (figures e-3 and e-4). The PCA results
within individual datasets confirmed that TMS, TFC,
SDMT, and SWR contributed similarly to the first
principal component, accounting for 64%
(COHORT), 66% (CARE-HD), and 64% (2CARE)
of the total variability (figure e-2).
Sensitivity of the cUHDRS to clinical stage. We investi-
gated how the cUHDRS in TRACK-HD varied
across time (baseline and 12, 24, and 36 months)
within the 5 groups defined in that study: healthy
controls, pre-HD A ($10.8 years from HD motor
diagnosis), pre-HD B (#10.8 years from HD motor
diagnosis), stage I HD (motor diagnosis and TFC
score 11–13), and stage II HD (motor diagnosis and
TFC score 7–10). The results showed that the
cUHDRS was correlated with disease group and HD
stage at baseline and showed a regular pattern of
progression over time in the stage I/II HD groups,
with a decline of z1 point per year (figure e-5).
These results were replicated in COHORT
(figure e-5).
Figure 2 Longitudinal S/N ratio of individual UHDRS clinical measures (TFC, TMS, SDMT, SWR) and the
cUHDRS across the 4 studies and time points
Care HD5 Co-Enzyme Q10 and Remacemide: Evaluation in HD; Cohort5 Cooperative Huntington’s Disease Observational
Research Trial; cUHDRS5 composite Unified Huntington Disease Rating Scale; SDMT5 Symbol Digit Modality Test; S/N5
single-to-noise; SWR 5 Stroop Word Reading Test; TFC 5 Total Functional Capacity; TMS 5 Total Motor Score; 2Care 5
Coenzyme Q10 (CoQ) in Huntington Disease; UHDRS 5 Unified Huntington Disease Rating Scale.
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Association of the cUHDRS with longitudinal brain
changes. Whereas the association between clinical meas-
ures with brain volumes was statistically significant across
all comparisons at baseline and at the 12-month follow-
up (all p , 0.01), the cUHDRS retained the highest
magnitude, consistency, and statistically significant as-
sociations across all time points up to 36 months (figure
3). The associations between TFC and SDMT scores
and brain volume loss were similar to that of the
cUHDRS but weaker. The TMS showed relatively weak
longitudinal associations, as did the SWR (figure 3).
Meta-analysis results of the cUHDRS and individual
components across the datasets and test-retest reliability of
short-term CARE-HD data. Overall, the meta-analysis re-
vealed that on average an approximate 1-point decline in
the cUHDRS over the first year of follow-up corre-
sponded to an approximate 3-point increase in TMS and
an approximate 0.7-point decline in the TFC (figure e-
6). SDMT and SWR showed a similar decline across
datasets over time, whereas the TFC, TMS, and
cUHDRS showed heterogeneity at 12 and 24 (but not
36) months. This heterogeneity was driven by a steeper
pattern of decline in the CARE-HD cohort on the TMS,
TFC, and cUHDRSmeasures.We note that participants
of CARE-HD showed evidence of more progressed dis-
ease at baseline, as demonstrated by a significantly
increased CAG3 age product score8 (mean CAG3 age
product score5 516.9, SD5 139.2; F3, 1,6655 6.49, p
, 0.001), which is an index of disease burden (table 1).
We assessed the test-retest reliability of the
cUHDRS using short-term baseline and 1-month
Figure 3 Comparative baseline and longitudinal association of individual UHDRS clinical measures and the
cUHDRS with measures of progressive corticostriatal atrophy in TRACK-HD
Pearson correlation coefficient 2-sided p values: *p , 0.05, **p , 0.01, ***p , 0.001. cUHDRS 5 composite Unified
Huntington Disease Rating Scale; SDMT 5 Symbol Digit Modality Test; TFC 5 Total Functional Capacity; TMS 5 Total
Motor Score; UHDRS 5 Unified Huntington Disease Rating Scale.
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data available in the CARE-HD dataset, given that
over a short period of time, we would expect to see
little change in disease severity. The results (ICC2,1
5 0.96)9 showed excellent test-retest reliability of
the cUHDRS.
cUHDRS and sample size planning for a clinical trial.
Data from TRACK-HD were used to estimate the
required sample size for a significant slope difference in
a randomized clinical trial (see e-Methods).10 Treatment
effect was defined as the percentage improvement of the
treatment group slope relative to the placebo group
(25%, 50%, 75%). Trial duration of 24 and 36 months
with visits every 6 months was considered. The type I
error rate was 5%; the type II error rate was 20% (power
5 80%); and attrition was set to 10% at 24 months and
20% at 36 months. Table 2 shows the total sample size
(n/2 in each group) for the cUHDRS and for each
individual measure making up the cUHDRS. Smaller
sample size was associated with use of the cUHDRS
relative to individual outcome measures. The required
sample size using the cUHDRS could be as much as
55% smaller than the next best measure (e.g., compared
to TMS at 24 months).
DISCUSSION The enhanced sensitivity of the
cUHDRS to clinical change in early symptomatic HD
and its strong relationship to underlying brain changes
relative to the TFC and the TMS suggest that the
cUHDRS is an improved measure of clinical progres-
sion. The TFC3,6,11–13 and TMS14–19 provide reliable
and clinically validated outcome measures of global
function or motor signs characteristic of HD and thus
should remain useful primary outcomemeasures in clin-
ical trials. We note that the performance of the TFCwas
strong in the 2 clinical trial databases studied relative to
the cUHDRS. However, these 2 measures either do not
represent the affected underlying phenomenology of
HD (i.e., the TFC does not measure underlying motor,
cognition, or behavior directly) or, in the case of the
TMS, provide limited domain coverage. In summary,
our results suggest that the cUHDRS has greater statis-
tical power (i.e., lower type II error rate) to detect success
in clinical trials aiming to slow clinical progression rela-
tive to the TFC and TMS.
We have reached consensus that a slowing of clin-
ical decline in the range of 20% to 30% annually on
the cUHDRS (z0.2–0.3 points per year), equivalent
toz2.4 to 3.5 mo/y of time saved from progression,
can be used to define a clinically efficacious treatment
in this setting. Even a lower-magnitude slowing of
decline of z0.1 point per year or z10% might be
clinically meaningful, although the sample size
required to demonstrate such an effect may be pro-
hibitively large.
We have demonstrated that explicit introduction
of 2 cognitive measures provides not only enhanced
sensitivity to measure clinical progression in HD
but also enhanced domain coverage. This was demon-
strated by the consistent magnitude gain of the S/N
ratio relative to all other single measures or combina-
tions of measures studied. We note that a cognitive
domain–specific composite outcome measure has
been developed (i.e., the Huntington’s Disease
Cognitive Assessment Battery).20 This composite,
although promising, has not been validated longitu-
dinally.20 Certain components of the Huntington’s
Disease Cognitive Assessment Battery have been
examined in a longitudinal setting (i.e., in the
TRACK-HD 24-month study). It is notable that the
highest sensitivity to longitudinal clinical change was
indeed observed for the SDMT and SWR at 24
months, the 2 key cognitive components of the
cUHDRS, along with a measure of circle tracing.21
Within the UHDRS, the PBA measure has known
poor longitudinal sensitivity to clinical change,22 which
we also observed. The PBA-apathy measure possessed
a relatively strong pattern of progression, but it did not
correlate well to either the cognitive or motor domain.
Although the cUHDRS does not contain behavioral
measures, our results suggest that behavioral measures
either are not key clinical features of clinical progres-
sion or appear unrelated to the progressive cognitive
and motor domains (i.e., the PBA-apathy score). The
apathy domain merits additional investigation in
Table 2 Estimated total sample size for a 2-arm randomized clinical trial
Duration, y Treatment effect, % cUHDRS, n TFC, n TMS, n SDMT, n SWR, n
2 25 430 1,096 960 984 1,059
2 50 108 274 240 246 265
2 75 48 122 107 109 118
3 25 341 858 634 590 539
3 50 85 215 158 148 135
3 75 38 95 70 66 60
Abbreviations: cUHDRS 5 Unified Huntington Disease Rating Scale; SDMT 5 Symbol Digit Modality Test; SWR 5 Stroop Word Reading Test; TFC 5 Total
Functional Capacity; TMS 5 Total Motor Score.
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clinical trials because it is clearly related to function and
showed a relatively strong pattern of progression. How-
ever, other behavioral measures of emotion recognition
or depressive symptoms are likely not good candidate
outcome measures of clinical progression.
A critical assumption underlying the proposed use
of the cUHDRS in clinical trials is that if a putative
neuroprotective or mutant huntingtin-lowering ther-
apy successfully targets disease mechanisms underly-
ing clinical progression, then each individual
measure making up the cUHDRS should move in
the same direction of improvement in response to this
treatment. A limitation with any composite is that
such specificity is lost in the interpretation of statisti-
cal results. If the cUHDRS shows success in a clinical
trial, then the conclusion is that the treatment posi-
tively affected motor, cognitive, daily functioning,
or some combination thereof.
However, the association over time between the
individual motor, cognitive, and global functional
clinical measures as observed here, as well as the
robust association between brain changes and the
composite, is supportive of the assumption that
the measures would tend to change together in
early HD in response to a treatment designed to
slow clinical progression. Another scenario might
involve slowing of decline on the cUHDRS but dis-
sociation between this and changes in behavioral
measures such as apathy or depression. In such
a scenario, arguably the clinical meaningfulness of
a treatment effect on the cUHDRS may be limited.
The cUHDRS can assist in ensuring that trials tar-
geting clinical progression are maximally sensitive to
detect clinical change andmaximally protected from fail-
ure due to measurement insensitivity. Similarly, insofar
as multidomain decline is measurable in this composite
measure, a more holistic clinically meaningful outcome
is obtained, similar to the use of the Clinical Dementia
Rating sum of boxes in Alzheimer disease, which con-
tains multidomain cognitive and global functional ele-
ments,23 or the practice of summing parts I, II, and
III of the Unified Parkinson Disease Rating Scale24 in
Parkinson disease. Moreover, trials can be conducted
more efficiently with smaller sample sizes with the
cUHDRS. The benefits are the lessening of participant
burden, using fewer resources to test hypotheses, and
potentially enhancing the quality of results obtained
through limiting the overall size of the trial. The
observed robust gain in S/N ratio of the cUHDRS
relative to the individual measures across the 4 studies
suggests that our findings are generalizable to a broader
early HD population. We have leveraged the knowledge
accrued from these previously conducted observational
and interventional studies, such that trials targeting clin-
ical progression in early HD can now better meet the
mandate of a robust primary outcome.
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